drugset
drugset / Trial / NCT07801287

Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC

NCT07801287 ↗

Phase 2 Recruiting 20 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable intermediate-stage hepatocellular carcinoma.. The objective is to explore potential survival benefits for this population and provide patients with more effective treatment options.

Timeline

Start
2026-09-01
Primary completion
2028-08-15
Completion
2028-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Iparomlimab Monoclonal antibody — Intravenous
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Tuvonralimab Monoclonal antibody — Intravenous

Indications

hepatocellular carcinoma